Search

Your search keyword '"Wester, Hans‐Jürgen"' showing total 1,474 results
Start Over Author "Wester, Hans‐Jürgen"
1,474 results on '"Wester, Hans‐Jürgen"'

201. Multiparametric PET and MRI of myocardial damage after myocardial infarction: correlation of integrin αvβ3 expression and myocardial blood flow

Author

Makowski, Marcus R., primary, Rischpler, Christoph, additional, Ebersberger, Ullrich, additional, Keithahn, Alexandra, additional, Kasel, Markus, additional, Hoffmann, Ellen, additional, Rassaf, Tienush, additional, Kessler, Horst, additional, Wester, Hans-Jürgen, additional, Nekolla, Stephan G., additional, Schwaiger, Markus, additional, and Beer, Ambros J., additional

Published
2020
Full Text
View/download PDF

203. [68Ga]-NODAGA-RGD Positron Emission Tomography (PET) for Assessment of Post Myocardial Infarction Angiogenesis as a Predictor for Left Ventricular Remodeling in Mice after Cardiac Stem Cell Therapy

Author

Lang, Cajetan Immanuel, primary, Döring, Piet, additional, Gäbel, Ralf, additional, Vasudevan, Praveen, additional, Lemcke, Heiko, additional, Müller, Paula, additional, Stenzel, Jan, additional, Lindner, Tobias, additional, Joksch, Markus, additional, Kurth, Jens, additional, Bergner, Carina, additional, Wester, Hans-Jürgen, additional, Ince, Hüseyin, additional, Steinhoff, Gustav, additional, Vollmar, Brigitte, additional, David, Robert, additional, and Krause, Bernd Joachim, additional

Published
2020
Full Text
View/download PDF

205. CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma

Author

Herhaus, Peter, primary, Lipkova, Jana, additional, Lammer, Felicitas, additional, Yakushev, Igor, additional, Vag, Tibor, additional, Slotta-Huspenina, Julia, additional, Habringer, Stefan, additional, Lapa, Constantin, additional, Pukrop, Tobias, additional, Hellwig, Dirk, additional, Wiestler, Benedikt, additional, Buck, Andreas K., additional, Deckert, Martina, additional, Wester, Hans-Jürgen, additional, Bassermann, Florian, additional, Schwaiger, Markus, additional, Weber, Wolfgang, additional, Menze, Björn, additional, and Keller, Ulrich, additional

Published
2020
Full Text
View/download PDF

207. Noninvasive Visualization of the Activated alphavbeta3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD

Author

Haubner Roland, Weber Wolfgang A, Beer Ambros J, Vabuliene Eugenija, Reim Daniel, Sarbia Mario, Becker Karl-Friedrich, Goebel Michael, Hein Rüdiger, Wester Hans-Jürgen, Kessler Horst, and Schwaiger Markus

Subjects
Oncology, Medicine
Abstract

Background The integrin alphavbeta3 plays an important role in angiogenesis and tumor cell metastasis, and is currently being evaluated as a target for new therapeutic approaches. Several techniques are being studied to enable noninvasive determination of alphavbeta3 expression. We developed [18F]Galacto-RGD, a 18F-labeled glycosylated alphavbeta3 antagonist, allowing monitoring of alphavbeta3 expression with positron emission tomography (PET). Methods and Findings Here we show by quantitative analysis of images resulting from a small-animal PET scanner that uptake of [18F]Galacto-RGD in the tumor correlates with alphavbeta3 expression subsequently determined by Western blot analyses. Moreover, using the A431 human squamous cell carcinoma model we demonstrate that this approach is sensitive enough to visualize alphavbeta3 expression resulting exclusively from the tumor vasculature. Most important, this study shows, that [18F]Galacto-RGD with PET enables noninvasive quantitative assessment of the alphavbeta3 expression pattern on tumor and endothelial cells in patients with malignant tumors. Conclusions Molecular imaging with [18F]Galacto-RGD and PET can provide important information for planning and monitoring anti-angiogenic therapies targeting the alphavbeta3 integrins and can reveal the involvement and role of this integrin in metastatic and angiogenic processes in various diseases.

Published
2005
Full Text
View/download PDF

208. Structural modifications of PSMA ligands to optimize their pharmacokinetics

Author

Wester, Hans-Jürgen (Prof. Dr.), Wester, Hans-Jürgen (Prof. Dr.);Eiber, Matthias (Priv.-Doz. Dr.), Schmidt, Alexander, Wester, Hans-Jürgen (Prof. Dr.), Wester, Hans-Jürgen (Prof. Dr.);Eiber, Matthias (Priv.-Doz. Dr.), and Schmidt, Alexander

Abstract

The prostate specific membrane antigen (PSMA) was recognized as promising molecular target and enabled the development of radiolabeled tracer for prostate cancer imaging and endoradiotherapy. Goal of this work was the development and identification of modifications to optimize the pharmacokinetics of ligands based on PSMA I&T. The optimization led to the design of the trimesic acid substituted ligand PSMA-66, which is a remarkably potent tracer with advanced tumor-targeting and pharmacokinetic properties., Das Prostata spezifische Membranantigen wurde als vielversprechende Zielstruktur entdeckt und ermöglichte die Entwicklung von Radioliganden für die Diagnostik und Endoradiotherapie des Prostatecarcinoms. Ziel dieser Arbeit war die Identifikation von Modifikationen welche die Pharmakokinetik PSMA I&T basierter Liganden optimieren können. Die Optimierung führte zum Trimesinsäure substituierten Liganden PSMA-66. Dieser potente Ligand zeichnet sich durch eine verbesserte Tumoranreicherung und optimierte Pharmakokinetik aus.

Published
2018

209. Development of cyclic pentapeptide ligands for chemokine receptor targeting

Author

Wester, Hans-Jürgen (Prof. Dr.), Wester, Hans-Jürgen (Prof. Dr.);Scheidhauer, Klemens M. (Prof. Dr.), Osl, Theresa, Wester, Hans-Jürgen (Prof. Dr.), Wester, Hans-Jürgen (Prof. Dr.);Scheidhauer, Klemens M. (Prof. Dr.), and Osl, Theresa

Abstract

Due to its pivotal role in tumor growth and metastasis in several types of human cancer, the chemokine receptor 4 (CXCR4) represents an innovative target for both diagnostic imaging and endoradio-therapeutic approaches. This work focused on the development of further optimized, CXCR4 targeting peptides for PET imaging (68Ga, 18F), fluorescence microscopy (fluorescent dye), and endoradiotherapy (177Lu) of CXCR4+ malignancies., Der Chemokin Rezeptor Typ 4 (CXCR4) ist unter Anderem am Wachstum und an der Metastasierung von Tumoren, sowie an Entzündungsprozessen im Körper beteiligt und eignet sich daher hervorragend als Zielstruktur sowohl für die diagnostische Bildgebung, als auch für therapeutische Ansätze. Ziel dieser Arbeit war die Entwicklung neuer CXCR4 gerichteter Peptide für die PET-Diagnostik, Fluoreszenzmikroskopie und Endoradiotherapie von CXCR4 assoziierten Krankheiten.

Published
2018

216. Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3.

Author

Knorr, Karina, Oh, So Won, Krönke, Markus, Wurzer, Alexander, D'Alessandria, Calogero, Herz, Michael, Weber, Wolfgang, Wester, Hans-Jürgen, Eiber, Matthias, Yusufi, Nahid, and Nekolla, Stephan

Subjects
PANCREAS, RADIATION dosimetry, LUNGS, IMAGE quality analysis, SUBMANDIBULAR gland, PAROTID glands, SALIVARY glands
Abstract

Background: Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands such as 18F-rhPSMA-7 are a new class of theranostic agents in clinical development for prostate cancer. We compared preclinical dosimetry and human biodistribution of 18F-rhPSMA-7 with that of single diastereoisomer form, 18F-rhPSMA-7.3. Methods: Preclinical dosimetry was performed with SCID-mice sacrificed at multiple timepoints (10–300 min) post-injection of 25.6 ± 3.6 MBq 18F-rhPSMA-7 or 28.5 ± 4.8 MBq 18F-rhPSMA-7.3 (n = 3–6 mice per timepoint). Heart, lung, liver, spleen, pancreas, fat, stomach, small intestine, large intestine, kidney, muscle, bone, bladder, testicles, tail, and brain tissue were harvested, and urine and blood samples collected. Percentage of injected dose per gram was calculated. Absorbed doses were estimated with OLINDA/EXM 1.0. 18F-rhPSMA-7 (n = 47) and 18F-rhPSMA-7.3 (n = 33) PET/CT exams were used to estimate human biodistribution. Mean (range) injected activities were 324 (236–424) MBq versus 345 (235–420) MBq, and acquisition times were 84 (42–166) versus 76 (59–122) minutes for 18F-rhPSMA-7 versus 18F-rhPSMA-7.3, respectively. SUVmean was determined for background (gluteal muscle), normal organs (salivary glands, blood pool, lung, liver, spleen, pancreas, duodenum, kidney, bladder, bone) and up to three representative tumour lesions. Qualitative analyses assessed image quality, non-specific blood pool activity, and background uptake in bone/marrow using 3/4-point scales. Results: Preclinical dosimetry revealed that at 3.5 h and 1 h bladder voiding intervals, the extrapolated total effective doses were 26.6 and 12.2 µSv/MBq for 18F-rhPSMA-7 and 21.7 and 12.8 µSv/MBq for 18F-rhPSMA-7.3 respectively. Human biodistribution of both agents was typical of other PSMA-ligands and broadly similar to each other; SUVmean were 16.9 versus 16.2 (parotid gland), 19.6 versus 19.9 (submandibular gland), 2.0 versus 1.9 (blood pool, p < 0.005), 0.7 versus 0.7 (lungs), 7.0 versus 7.3 (liver), 9.1 versus 8.4 (spleen), 32.4 versus 35.7 (kidney), 2.5 versus 2.8 (pancreas), 10.9 versus 11.0 (duodenum), 1.1 versus 1.3 (bone) and 4.6 versus 2.0 (bladder; p < 0.001) for 18F-rhPSMA-7 versus 18F-rhPSMA-7.3, respectively. Tumour SUVmean was higher for 18F-rhPSMA-7.3 (32.5 ± 42.7, n = 63 lesions) than for 18F-rhPSMA-7 (20.0 ± 20.2, n = 89 lesions). Conclusions: Radiation dosimetry is favourable for both agents. Radiation exposure, assuming a 1 h voiding interval, is less than 5 mSv after injection of 370 MBq. 18F-rhPSMA-7.3 showed significantly lower bladder uptake, and a higher uptake trend in tumours compared with 18F-rhPSMA-7. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

221. From a Helix to a Small Cycle: Metadynamics-Inspired αvβ6 Integrin Selective Ligands

Author

Di Leva, Francesco Saverio, Tomassi, Stefano, Di Maro, Salvatore, Reichart, Florian, Notni, Johannes, Dangi, Abha, Marelli, Udaya Kiran, Brancaccio, Diego, Merlino, Francesco, Wester, Hans-Jürgen, Novellino, Ettore, Kessler, Horst, Marinelli, Luciana, Dileva, Francesco Saverio, Tomassi, Stefano, Dimaro, Salvatore, Reichart, Florian, Notni, Johanne, Dangi, Abha, Marelli, Udaya Kiran, Brancaccio, Diego, Merlino, Francesco, Wester, Hans-Jürgen, Novellino, Ettore, Kessler, Horst, Marinelli, Luciana, Di Leva, Francesco Saverio, and Di Maro, Salvatore

Subjects
0301 basic medicine, Integrins, Peptidomimetic, drug design, Medizin, 010402 general chemistry, 01 natural sciences, Catalysis, integrin ligands, drug design, metadynamics, cancer, molecular imaging, 03 medical and health sciences, Antigens, Neoplasm, In vivo, Humans, cancer, integrin ligand, Receptor, Nuclear Magnetic Resonance, Biomolecular, Chemistry, Metadynamics, Rational design, General Chemistry, molecular imaging, 0104 chemical sciences, Molecular Docking Simulation, 030104 developmental biology, Docking (molecular), Biophysics, metadynamic, Molecular imaging, Alpha helix
Abstract

The RGD-recognizing αvβ6 integrin has only recently emerged as a major target for cancer diagnosis and therapy. Thus, the development of selective, low molecular weight ligands of this receptor is still of great demand. Here, a metadynamics-driven design strategy allowed us to successfully convert a helical nonapeptide into a cyclic pentapeptide (6) showing remarkable potency and αvβ6 specificity. NMR and docking studies elucidated the reasons for the high affinity and selectivity of this compound, setting the ground for the rational design of new αvβ6-specific small sized peptides or even peptidomimetics. In vivo PET imaging studies demonstrated the potential use of 6 for medical applications.

Published
2018

222. Innovative Complexation Strategies for the Introduction of Short-lived PET Isotopes into Radiopharmaceuticals

Author

Kessler, Horst (Prof. Dr. Dr. h.c.), Schwaiger, Markus (Prof. Dr.), Wester, Hans-Jürgen P. (Prof. Dr., Wester, Hans-Jürgen P. (Prof. Dr.), Simecek, Jakub, Kessler, Horst (Prof. Dr. Dr. h.c.), Schwaiger, Markus (Prof. Dr.), Wester, Hans-Jürgen P. (Prof. Dr., Wester, Hans-Jürgen P. (Prof. Dr.), and Simecek, Jakub

Abstract

A number of TRAP (Triazacyclononane-triphosphinate) chelators were evaluated for labelling with Gallium-68. Based on the obtained data, a novel bifunctional chelator NOPO was designed, synthesised and employed for preparation of Ga-68 radiopharmaceuticals. Several 68Ga-labelled NOPO peptidic conjugates showed promising results in preclinical positron emission tomography (PET) imaging studies using the mice models. Moreover, NOPO was found also suitable for labelling with Copper-64., Eine Serie von TRAP-(Triazacyclononan-Trisphosphinat)-Chelatoren wurde bezüglich ihrer Gallium-68-Markierungseigenschaften charakterisiert. Darauf aufbauend wurde NOPO, ein neuer bifunktioneller Chelator für die Verwendung in Gallium-68-Radiopharmaka, entworfen und synthetisiert. Einige Gallium-68-markierte NOPO-Peptid-Konjugate wurden erfolgreich für die präklinische Positronenemissionstomographie-Bildgebung im Mausmodell eingesetzt. NOPO ist zudem für die Verwendung mit Kupfer-64 geeignet.

Published
2017

223. Development of Diagnostic and Therapeutic Radiopharmaceuticals targeting the Chemokine Receptor CXCR4

Author

Wester, Hans-Jürgen (Prof. Dr.), Wester, Hans-Jürgen (Prof. Dr.);Scheidhauer, Klemens (Prof. Dr.), Poschenrieder, Andreas, Wester, Hans-Jürgen (Prof. Dr.), Wester, Hans-Jürgen (Prof. Dr.);Scheidhauer, Klemens (Prof. Dr.), and Poschenrieder, Andreas

Abstract

The chemokine receptor 4 (CXCR4) and C-X-C chemokine ligand 12 (CXCL12) play a fundamental role in various diseases. CXCR4 is overexpressed in over 23 different tumor types and presents an important molecular target for drug development. The presented thesis shows the development and (pre)clinical evaluation of CXCR4-targeted diagnostic and therapeutic radiopharmaceuticals, i.e. cyclic pentapeptides that have been labeled with 18F, 64Cu, or 68Ga for positron emission tomography (PET), and a first CXCR4-directed 90Y or 177Lu-labeled analog for peptide receptor radionuclide therapy., Der CXC-Motiv-Chemokinrezeptor 4 (CXCR4) spielt mit seinem Liganden CXC-Motiv-Chemokin 12 (CXCL12) eine Schlüsselrolle in verschiedenen Krankheiten. CXCR4 ist auf über 23 verschiedenen Tumorarten verstärkt exprimiert und stellt ein wichtiges Ziel für die Arzneimittelentwicklung dar. In der Doktorarbeit wurden CXCR4-gerichtete diagnostische und therapeutische Radiopharmaka entwickelt und (prä)klinisch evaluiert. Neben zyklischen Pentapeptiden für die Positronen-Emissions-Tomographie (PET, markiert mit 18F, 64Cu oder 68Ga) wird das erste CXCR4-gerichtete Peptid für die Peptid-Rezeptor-Radionuklid-Therapie vorgestellt.

Published
2017

224. Innovative Complexation Strategies for the Introduction of Short-lived PET Isotopes into Radiopharmaceuticals

Author

Wester, Hans-Jürgen P. (Prof. Dr., Wester, Hans-Jürgen P. (Prof. Dr.);Kessler, Horst (Prof. Dr. Dr. h.c.);Schwaiger, Markus (Prof. Dr.), Simecek, Jakub, Wester, Hans-Jürgen P. (Prof. Dr., Wester, Hans-Jürgen P. (Prof. Dr.);Kessler, Horst (Prof. Dr. Dr. h.c.);Schwaiger, Markus (Prof. Dr.), and Simecek, Jakub

Abstract

A number of TRAP (Triazacyclononane-triphosphinate) chelators were evaluated for labelling with Gallium-68. Based on the obtained data, a novel bifunctional chelator NOPO was designed, synthesised and employed for preparation of Ga-68 radiopharmaceuticals. Several 68Ga-labelled NOPO peptidic conjugates showed promising results in preclinical positron emission tomography (PET) imaging studies using the mice models. Moreover, NOPO was found also suitable for labelling with Copper-64., Eine Serie von TRAP-(Triazacyclononan-Trisphosphinat)-Chelatoren wurde bezüglich ihrer Gallium-68-Markierungseigenschaften charakterisiert. Darauf aufbauend wurde NOPO, ein neuer bifunktioneller Chelator für die Verwendung in Gallium-68-Radiopharmaka, entworfen und synthetisiert. Einige Gallium-68-markierte NOPO-Peptid-Konjugate wurden erfolgreich für die präklinische Positronenemissionstomographie-Bildgebung im Mausmodell eingesetzt. NOPO ist zudem für die Verwendung mit Kupfer-64 geeignet.

Published
2017

225. [68Ga]-Pentixafor PET/CT for CXCR4-mediated imaging of vestibular schwannomas

Author

Breun, Maria, Monoranu, Camelia M., Kessler, Almuth F., Matthies, Cordula, Löhr, Mario, Hagemann, Carsten, Schirbel, Andreas, Rowe, Steven P., Pomper, Martin G., Buck, Andreas K., Wester, Hans-Jürgen, Ernestus, Ralf-Ingo, and Lapa, Constantin

Subjects
ddc:610
Abstract

We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [\(^{68}\)Ga]Pentixafor. Methods: 4 patients with 6 primarily diagnosed or pre-treated/observed VS were enrolled. All subjects underwent [\(^{68}\)Ga]Pentixafor PET/CT prior to surgical resection. Images were analyzed visually and semi-quantitatively for CXCR4 expression including calculation of tumor-to-background ratios (TBR). Immunohistochemistry served as standard of reference in three patients. Results: [\(^{68}\)Ga]Pentixafor PET/CT was visually positive in all cases. SUV\(_{mean}\) and SUV\(_{max}\) were 3.0 ± 0.3 and 3.8 ± 0.4 and TBR\(_{mean}\) and TBR\(_{max}\) were 4.0 ± 1.4 and 5.0 ± 1.7, respectively. Histological analysis confirmed CXCR4 expression in tumors. Conclusion: Non-invasive imaging of CXCR4 expression using [\(^{68}\)Ga]Pentixafor PET/CT of VS is feasible and could prove useful for in vivo assessment of CXCR4 expression.

Published
2019

226. The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model

Author

Begum, Nusrat J., Glatting, Gerhard, Wester, Hans-Jürgen, Eiber, Matthias, Beer, Ambros J., and Kletting, Peter

Subjects
Glutamate Carboxypeptidase II, Male, Prostatic neoplasms, Therapy, Predictive medicine, lcsh:Medicine, Modellierung, Ligands, Models, Biological, Article, Drug design, Targeted therapies, Positron Emission Tomography Computed Tomography, Small Molescules, Computational models, Humans, Pharmacokinetics, ddc:610, lcsh:Science, Prostatakrebs, Tumor, Pharmakokinetik, lcsh:R, Computational science, Prostatic Neoplasms, Binding, Endocytosis, Nanomedizin, Antigens, Surface, lcsh:Q, DDC 610 / Medicine & health
Abstract

The aim of this work was to investigate the effect of ligand amount, affinity and internalization of prostate-specific membrane antigen (PSMA)-specific ligands on the activity concentrations for PET/ CT imaging and on the absorbed doses for therapy. A physiologically-based pharmacokinetic (PBPK) model for PSMA-specific ligands was implemented. Thirteen virtual patients with metastatic castrationresistant prostate cancer were analysed. Simulations were performed for different combinations of association rates kon (0.1���0.01 L/nmol/min), dissociation rates koff (0.1���0.0001 min���1), internalization rates ��int (0.01���0.0001 min���1) and ligand amounts (1���1000 nmol). For imaging the activity was normalized to volume and injected activity (68Ga-PSMA at 1 h). For therapy the absorbed dose was calculated for 7.3 �� 0.3 GBq 177Lu-PSMA. The effect of the investigated parameters on therapy were larger compared to imaging. For imaging, the combination of properties leading to the highest tumour uptake was kon = 0.1 L/nmol/min, koff = 0.01 min���1 for typical ligand amounts (1���10 nmol). For therapy, the higher the internalization rate, the larger was the required ligand amount for optimal tumour-tokidney ratios. The higher the affinity, the more important was the choice of the optimal ligand amount. PBPK modelling provides insight into the pharmacokinetics of PSMA-specific ligands. Further in silico and in vivo studies are required to verify the influence of the analysed parameters., publishedVersion

Published
2019
Full Text
View/download PDF

227. CXCR4-directed imaging in solid tumors

Author

Werner, Rudolf A., Kircher, Stefan, Higuchi, Takahiro, Kircher, Malte, Schirbel, Andreas, Wester, Hans-Jürgen, Buck, Andreas K., Pomper, Martin G., Rowe, Steven P., and Lapa, Constantin

Subjects
ddc:610
Abstract

Despite histological evidence in various solid tumor entities, available experience with CXCR4-directed diagnostics and endoradiotherapy mainly focuses on hematologic diseases. With the goal of expanding the application of CXCR4 theranostics to solid tumors, we aimed to elucidate the feasibility of CXCR4-targeted imaging in a variety of such neoplasms. Methods: Nineteen patients with newly diagnosed, treatment-naïve solid tumors including pancreatic adenocarcinoma or neuroendocrine tumor, cholangiocarcinoma, hepatocellular carcinoma, renal cell carcinoma, ovarian cancer, and prostate cancer underwent [\(^{68}\)Ga]Pentixafor PET/CT. CXCR4-mediated uptake was assessed both visually and semi-quantitatively by evaluation of maximum standardized uptake values (SUV\(_{max}\)) of both primary tumors and metastases. With physiologic liver uptake as reference, tumor-to-background ratios (TBR) were calculated. [\(^{68}\)Ga]Pentixafor findings were further compared to immunohistochemistry and [\(^{18}\)F]FDG PET/CT. Results: On [\(^{68}\)Ga]Pentixafor PET/CT, 10/19 (52.6%) primary tumors were visually detectable with a median SUVmax of 5.4 (range, 1.7–16.0) and a median TBR of 2.6 (range, 0.8–7.4), respectively. The highest level of radiotracer uptake was identified in a patient with cholangiocarcinoma (SUVmax, 16.0; TBR, 7.4). The relatively low uptake on [\(^{68}\)Ga]Pentixafor was also noted in metastases, exhibiting a median SUVmax of 4.5 (range, 2.3–8.8; TBR, 1.7; range, 1.0–4.1). A good correlation between uptake on [\(^{68}\)Ga]Pentixafor and histological derived CXCR4 expression was noted (R = 0.62, P < 0.05). In the 3 patients in whom [\(^{18}\)F]FDG PET/CT was available, [\(^{68}\)Ga]Pentixafor exhibited lower uptake in all lesions. Conclusions: In this cohort of newly diagnosed, treatment-naïve patients with solid malignancies, CXCR4 expression as detected by [\(^{68}\)Ga]Pentixafor-PET/CT and immunohistochemistry was rather moderate. Thus, CXCR4-directed imaging may not play a major role in the management of solid tumors in the majority of patients.

Published
2019

228. EANM procedure guidelines for radionuclide therapy with ¹⁷⁷Lu-labelled PSMA-ligands (¹⁷⁷Lu-PSMA-RLT)

Author

Kratochwil, Clemens, Fendler, Wolfgang Peter, Eiber, Matthias, Baum, Richard, Bozkurt, Murat Fani, Czernin, Johannes, Delgado Bolton, Roberto C., Ezziddin, Samer, Forrer, Flavio, Hicks, Rodney J., Hope, Thomas A., Kabasakal, Levant, Konijnenberg, Mark, Kopka, Klaus, Lassmann, Michael, Mottaghy, Felix M., Oyen, Wim, Rahbar, Kambiz, Schöder, Heiko, Virgolini, Irene, Wester, Hans-Jürgen, Bodei, Lisa, Fanti, Stefano, Haberkorn, Uwe, and Herrmann, Ken

Subjects
Medizin
Published
2019

232. CXCR4-Directed Imaging in Solid Tumors

Author

Werner, Rudolf A., Kircher, Stefan, Higuchi, Takahiro, Kircher, Malte, Schirbel, Andreas, Wester, Hans-Jürgen, Buck, Andreas K., Pomper, Martin G., Rowe, Steven P., and Lapa, Constantin

Subjects
ddc
Published
2018

233. Klinisches Outcome der PSMA-radioguided surgery beim rezidivierten Prostatakarzinom

Author

Horn, Thomas, Rauscher, Isabel, Eiber, Matthias, Wester, Hans-Jürgen, Schottelius, Margret, Heck, Matthias, Gschwend, Jürgen, and Maurer, Tobias

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Eine Fusionsbildgebung mittels CT und PSMA-gerichteter Positronen-Emissionstomographie erlaubt auch bei niedrigen PSA-Werten eine gute Detektion und Lokalisation eines Rezidivs nach kurativer Therapie eines Prostatakarzinoms. Eine Resektion dieses Rezidivs könnte zumindest für [zum vollständigen Text gelangen Sie über die oben angegebene URL], 44. gemeinsamen Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie

Published
2018

237. 18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy

Author

Eiber, Matthias, primary, Kroenke, Markus, additional, Wurzer, Alexander, additional, Ulbrich, Lena, additional, Jooß, Lena, additional, Maurer, Tobias, additional, Horn, Thomas, additional, Schiller, Kilian, additional, Langbein, Thomas, additional, Buschner, Gabriel, additional, Wester, Hans-Jürgen, additional, and Weber, Wolfgang, additional

Published
2019
Full Text
View/download PDF

238. Histologically Confirmed Diagnostic Efficacy of 18F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer

Author

Kroenke, Markus, primary, Wurzer, Alexander, additional, Schwamborn, Kristina, additional, Ulbrich, Lena, additional, Jooß, Lena, additional, Maurer, Tobias, additional, Horn, Thomas, additional, Rauscher, Isabel, additional, Haller, Bernhard, additional, Herz, Michael, additional, Wester, Hans-Jürgen, additional, Weber, Wolfgang A., additional, and Eiber, Matthias, additional

Published
2019
Full Text
View/download PDF

239. Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, 18F-rhPSMA-7, in Patients with Prostate Cancer

Author

Oh, So Won, primary, Wurzer, Alexander, additional, Teoh, Eugene J., additional, Oh, Sohee, additional, Langbein, Thomas, additional, Krönke, Markus, additional, Herz, Michael, additional, Kropf, Saskia, additional, Wester, Hans-Jürgen, additional, Weber, Wolfgang A., additional, and Eiber, Matthias, additional

Published
2019
Full Text
View/download PDF

240. Prostate-Specific Membrane Antigen–Guided Surgery

Author

Maurer, Tobias, primary, Graefen, Markus, additional, van der Poel, Henk, additional, Hamdy, Freddie, additional, Briganti, Alberto, additional, Eiber, Matthias, additional, Wester, Hans-Jürgen, additional, and van Leeuwen, Fijs W.B., additional

Published
2019
Full Text
View/download PDF

241. CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma

Author

Herhaus, Peter, primary, Lipkova, Jana, additional, Lammer, Felicitas, additional, Slotta-Huspenina, Julia, additional, Wiestler, Benedikt, additional, Vag, Tibor, additional, Habringer, Stefan, additional, Yakushev, Igor, additional, Lapa, Constantin, additional, Pukrop, Tobias, additional, Hellwig, Dirk, additional, Buck, Andreas, additional, Deckert, Martina, additional, Wester, Hans-Jürgen, additional, Bassermann, Florian, additional, Weber, Wolfgang, additional, Schwaiger, Markus, additional, Menze, Björn, additional, and Keller, Ulrich, additional

Published
2019
Full Text
View/download PDF

245. Myocardial infarction triggers cardioprotective antigen-specific T helper cell responses

Author

Rieckmann, Max, primary, Delgobo, Murilo, additional, Gaal, Chiara, additional, Büchner, Lotte, additional, Steinau, Philipp, additional, Reshef, Dan, additional, Gil-Cruz, Cristina, additional, Horst, Ellis N. ter, additional, Kircher, Malte, additional, Reiter, Theresa, additional, Heinze, Katrin G., additional, Niessen, Hans W.M., additional, Krijnen, Paul A.J., additional, van der Laan, Anja M., additional, Piek, Jan J., additional, Koch, Charlotte, additional, Wester, Hans-Jürgen, additional, Lapa, Constantin, additional, Bauer, Wolfgang R., additional, Ludewig, Burkhard, additional, Friedman, Nir, additional, Frantz, Stefan, additional, Hofmann, Ulrich, additional, and Ramos, Gustavo Campos, additional

Published
2019
Full Text
View/download PDF

246. Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer

Author

Horn, Thomas, primary, Krönke, Markus, additional, Rauscher, Isabel, additional, Haller, Bernhard, additional, Robu, Stephanie, additional, Wester, Hans-Jürgen, additional, Schottelius, Margret, additional, van Leeuwen, Fijs W.B., additional, van der Poel, Henk G., additional, Heck, Matthias, additional, Gschwend, Jürgen E., additional, Weber, Wolfgang, additional, Eiber, Matthias, additional, and Maurer, Tobias, additional

Published
2019
Full Text
View/download PDF

247. 68Ga-PSMA I&T PET/CT for primary staging of prostate cancer

Author

Cytawa, Wojciech, primary, Seitz, Anna Katharina, additional, Kircher, Stefan, additional, Fukushima, Kazuhito, additional, Tran-Gia, Johannes, additional, Schirbel, Andreas, additional, Bandurski, Tomasz, additional, Lass, Piotr, additional, Krebs, Markus, additional, Połom, Wojciech, additional, Matuszewski, Marcin, additional, Wester, Hans-Jürgen, additional, Buck, Andreas K., additional, Kübler, Hubert, additional, and Lapa, Constantin, additional

Published
2019
Full Text
View/download PDF

248. Somatostatin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

Author

Bosquet, Corinne, primary, Castaño, Justo P., primary, Csaba, Zsolt, primary, Culler, Micheal, primary, Dournaud, Pascal, primary, Epelbaum, Jacques, primary, Feniuk, Wasyl, primary, Harmar, Anthony, primary, Hills, Rebecca, primary, Hofland, Leo, primary, Hoyer, Daniel, primary, Humphrey, Patrick P. A., primary, Kreienkamp, Hans-Jürgen, primary, Lupp, Amelie, primary, Melmed, Shlomo, primary, Meyerhof, Wolfgang, primary, O'Carroll, Anne-Marie, primary, Patel, Yogesh C., primary, Reisine, Terry, primary, Reubi, Jean-Claude, primary, Schindler, Marcus, primary, Schmid, Herbert, primary, Schonbrunn, Agnes, primary, Schulz, Stefan, primary, Taylor, John E., primary, Tulipano, Giovanni, primary, Vezzani, Annamaria, primary, and Wester, Hans-Jürgen, primary

Published
2019
Full Text
View/download PDF

249. Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye–Protein Interaction

Author

Hensbergen, Albertus W., primary, Buckle, Tessa, additional, van Willigen, Danny M., additional, Schottelius, Margret, additional, Welling, Mick M., additional, van der Wijk, Felicia A., additional, Maurer, Tobias, additional, van der Poel, Henk G., additional, van der Pluijm, Gabri, additional, van Weerden, Wytske M., additional, Wester, Hans-Jürgen, additional, and van Leeuwen, Fijs W.B., additional

Published
2019
Full Text
View/download PDF

250. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)

Author

Kratochwil, Clemens, primary, Fendler, Wolfgang Peter, additional, Eiber, Matthias, additional, Baum, Richard, additional, Bozkurt, Murat Fani, additional, Czernin, Johannes, additional, Delgado Bolton, Roberto C., additional, Ezziddin, Samer, additional, Forrer, Flavio, additional, Hicks, Rodney J., additional, Hope, Thomas A., additional, Kabasakal, Levant, additional, Konijnenberg, Mark, additional, Kopka, Klaus, additional, Lassmann, Michael, additional, Mottaghy, Felix M., additional, Oyen, Wim, additional, Rahbar, Kambiz, additional, Schöder, Heiko, additional, Virgolini, Irene, additional, Wester, Hans-Jürgen, additional, Bodei, Lisa, additional, Fanti, Stefano, additional, Haberkorn, Uwe, additional, and Herrmann, Ken, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results